Between Evidence and Consensus | SIBCS Special Feature: Professor Jian Zhang on Consensus in Adjuvant and Advanced Breast Cancer Treatment and Prospective Updates to the 2027 “Little Red Book” Guidelines

Between Evidence and Consensus | SIBCS Special Feature: Professor Jian Zhang on Consensus in Adjuvant and Advanced Breast Cancer Treatment and Prospective Updates to the 2027 “Little Red Book” Guidelines

On October 16–17, the 19th National Breast Cancer Conference and the 21st Shanghai International Breast Cancer Conference (SIBCS) were successfully held in Shanghai. Under the chairmanship of Professor Jian Zhang from Fudan University Shanghai Cancer Center, voting was completed on the adjuvant and advanced disease sections of the “2027 Updates to the Guidelines and Consensus on the Diagnosis and Treatment of Breast Cancer.” Against this background, Oncology Frontier invited Professor Jian Zhang to discuss controversial issues in adjuvant and advanced breast cancer treatment, considerations in sequencing first- and second-line therapies for HER2-positive advanced breast cancer, and potential changes in the 2027 Guidelines and Consensus on the Diagnosis and Treatment of Breast Cancer (the “Little Red Book” guidelines).
ESMO Voices from China | Professor Wei Li: TELEGRAM Study Reveals Differences in Musculoskeletal Pain Outcomes Between Tuppefilgrastim and Other Long-Acting G-CSFs During Breast Cancer Chemotherapy

ESMO Voices from China | Professor Wei Li: TELEGRAM Study Reveals Differences in Musculoskeletal Pain Outcomes Between Tuppefilgrastim and Other Long-Acting G-CSFs During Breast Cancer Chemotherapy

Chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) are important complications that need to be prevented during breast cancer chemotherapy. The use of long-acting granulocyte colony-stimulating factors (G-CSFs) helps prevent these complications and supports the delivery of chemotherapy. At the same time, reducing treatment-related pain has become an important consideration in optimizing supportive care.
Between Sharpness and Gentleness | SIBCS Special Feature: Professors Yehui Shi, Jia Wang, and Benlong Yang on the Delicate Balance Between Precision and Compassion in Breast Cancer Care

Between Sharpness and Gentleness | SIBCS Special Feature: Professors Yehui Shi, Jia Wang, and Benlong Yang on the Delicate Balance Between Precision and Compassion in Breast Cancer Care

Sharpness and gentleness may appear to be two opposing qualities, but in clinical practice, they often need to coexist within the same treatment decision. During the 19th National Breast Cancer Conference and the 21st Shanghai International Breast Cancer Conference (SIBCS), Professor Benlong Yang of Fudan University Shanghai Cancer Center moderated a roundtable discussion entitled “The Dialectics of Sharpness and Gentleness.” He invited Professor Jia Wang of Zhongshan Hospital Affiliated to Dalian University and Professor Yehui Shi of Tianjin Medical University Cancer Institute and Hospital to explore, from surgical and medical oncology perspectives respectively, a question that runs throughout breast cancer care: When should we be sharp, and when should we be gentle? This article presents the discussion for our readers.
Between Evidence and Compassion | SIBCS Special Feature: Professor Peng Yuan on “Hearing the Sighs Behind Treatment Decisions” — Why Fertility Preservation for Young Breast Cancer Patients Must Begin Earlier

Between Evidence and Compassion | SIBCS Special Feature: Professor Peng Yuan on “Hearing the Sighs Behind Treatment Decisions” — Why Fertility Preservation for Young Breast Cancer Patients Must Begin Earlier

Breast cancer is increasingly affecting younger women. More and more young patients are achieving long-term survival while continuing to have a strong desire to have children. Fertility preservation has therefore become an important component of comprehensive breast cancer care. At the recently held 19th National Breast Cancer Conference and 21st Shanghai International Breast Cancer Conference (SIBCS), Oncology Frontier invited Professor Peng Yuan from the Cancer Hospital, Chinese Academy of Medical Sciences, to share her experience regarding fertility preservation in young breast cancer patients, the timing of discussions between physicians and patients, treatment regimens that may affect fertility, and multidisciplinary support strategies for patients who have missed the optimal window for fertility preservation.
Prof. Harry Paul Erba: Focusing on Precision Therapy for FLT3-Mutated AML and Exploring Resistance Management and MRD-Guided Strategies

Prof. Harry Paul Erba: Focusing on Precision Therapy for FLT3-Mutated AML and Exploring Resistance Management and MRD-Guided Strategies

With the growing adoption of targeted therapies including FLT3 inhibitors and menin inhibitors in the treatment landscape of acute myeloid leukemia (AML), optimizing therapeutic strategies, overcoming secondary resistance, and delivering precision care have emerged as key clinical priorities. Meanwhile, the value of measurable residual disease (MRD) monitoring is increasingly recognized in treatment response assessment, transplantation decision-making, and maintenance therapy.
ESMO Expert Commentary | Professor Jin Yang: From Design Rationale to the Clinical Landscape — Advancing ADC Therapy for HER2-Low Breast Cancer

ESMO Expert Commentary | Professor Jin Yang: From Design Rationale to the Clinical Landscape — Advancing ADC Therapy for HER2-Low Breast Cancer

The 2026 European Society for Medical Oncology (ESMO) Congress was held in Madrid, Spain, from October 23 to 27. At the meeting, several major studies in HER2-low breast cancer reported updated results. In particular, the presentation of large phase III clinical trial data for several novel HER2 ADCs sparked extensive discussion among experts. These findings not only offer new hope to patients but also prompt a closer examination of the relationship between different drug design strategies and clinical efficacy.
Professor Lei Zhang: Advancing Translational Research in Rare Bleeding Disorders and Expanding the Clinical Benefits of Gene Therapy for Hemophilia

Professor Lei Zhang: Advancing Translational Research in Rare Bleeding Disorders and Expanding the Clinical Benefits of Gene Therapy for Hemophilia

Precision diagnosis, standardized management, and therapeutic innovation in rare bleeding disorders remain important areas of focus in hematology. From improving patient registries and strengthening clinical diagnostic and treatment capabilities to deepening collaboration between basic and clinical research and promoting the translation of scientific discoveries, continued efforts are needed to ensure that more patients benefit from advances in the field. Meanwhile, breakthroughs in gene therapy for hemophilia have brought new hope for patients with inherited bleeding disorders. Oncology Frontier – Hematology Frontier invited Professor Lei Zhang of the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, to share his team's experience in translational research on rare bleeding disorders and discuss patient selection, implementation challenges, and future directions in gene therapy for hemophilia.
2026 IFSC | Professor Daichi Inoue Explores Clonal Evolution in Leukemia with Extremely Poor Prognosis: SETBP1 Abundance-Dependent Mechanisms and Early Intervention Strategies

2026 IFSC | Professor Daichi Inoue Explores Clonal Evolution in Leukemia with Extremely Poor Prognosis: SETBP1 Abundance-Dependent Mechanisms and Early Intervention Strategies

Basic stem cell research, regenerative medicine, cell therapy, and the application of clinical research guidelines are currently among the most closely watched frontiers in global hematology and translational medicine. With these topics at its core, the 10th International Forum on Stem Cells (IFSC) was successfully held, bringing together leading experts and scholars from around the world to explore scientific discoveries and technological innovation. The forum showcased the latest advances in basic, clinical, and translational research on hematopoietic stem cells, with the aim of promoting collaborative innovation in the global stem cell field. During the conference, Oncology Frontier – Hematology Frontier invited Professor Daichi Inoue of Osaka University, Japan, to share his latest research findings and perspectives on "Clonal Evolution and Targeted Intervention in Leukemia with Extremely Poor Prognosis." The key insights are presented below.
Professor Xi Zhang: Unmet Clinical Needs in Chronic GVHD in China and Strategies to Address Them

Professor Xi Zhang: Unmet Clinical Needs in Chronic GVHD in China and Strategies to Address Them

Allogeneic hematopoietic stem cell transplantation is an important potentially curative treatment for hematologic diseases. However, chronic graft-versus-host disease (GVHD), a common post-transplant complication, continues to have a substantial long-term impact on patients' quality of life. In China, significant clinical challenges remain in understanding the underlying mechanisms of the disease, achieving accurate diagnosis, implementing risk-stratified treatment, and providing long-term management.
2026 IFSC | Professor Naoki Hosen Explores Novel Targets for Cell Therapy in Hematologic Malignancies: Balancing Efficacy and Safety and Advancing from CAR-T to CAR-NK

2026 IFSC | Professor Naoki Hosen Explores Novel Targets for Cell Therapy in Hematologic Malignancies: Balancing Efficacy and Safety and Advancing from CAR-T to CAR-NK

Basic stem cell research, regenerative medicine, cell therapy, and the application of clinical research guidelines are currently among the most closely watched frontiers in global hematology and translational medicine. With these topics at its core, the 10th International Forum on Stem Cells (IFSC) was successfully held, bringing together leading experts and scholars from around the world to explore scientific discoveries and technological innovation. The forum showcased the latest advances in basic, clinical, and translational research on hematopoietic stem cells, with the aim of promoting collaborative innovation in the global stem cell field. During the conference, Oncology Frontier – Hematology Frontier invited Professor Naoki Hosen of Osaka University, Japan, to share his latest research findings and academic perspectives on "Beyond CD19/BCMA: An Overview of Novel Targets for CAR-T and NK Cell Therapy in Hematologic Malignancies." The key insights are presented below.